<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2 Final//EN">
<HTML>
<HEAD>
<LINK rel="stylesheet" type="text/css" href="be.css">
<META NAME="contextstring" CONTENT="Diureticsreducedcardiovasculardiseaseeventsindiabeticandnondiabeticpatients">
<META NAME="keywords" CONTENT="ACE inhibitors;Acute MI;Acute myocardial infarction;Adrenergic beta-antagonists;Adult-onset diabetes mellitus;AMI - acute myocardial infarction;Angiotensin I-converting enzyme inhibitors;Angiotensin-converting enzyme inhibition;Antihypertensive treatment;AODM;ARR;Arterial hypertension;ASHD;Atenolol;Atherosclerotic heart disease;B-adrenergic blockade;Benzothiadiazine diuretics;Beta blocker;Blood pressure, high;CAD;Cardiac death;Cardiac disease;Cardiac index;Cardiac mortality;Cardiovascular complications;Cardiovascular disease;Cardiovascular events;Cardiovascular mortality;Chlorthalidone;Chronic hypertension;Chronic hyponatremia;CI;Clinical depression;Clinical diabetes;Converting enzyme inhibitors;Coronary artery disease;Coronary artery stenosis;Coronary deaths;Coronary events;Coronary thrombosis;CVD;Depression;Depression screening;Depression, endogenous;Depressive disorder;Diabetes mellitus;Diabetes mellitus, type I;Diabetes mellitus, type II;Diabetic;Diabetic patients;Diastolic blood pressure;Diuretic thiazide;Diuretics;Drug reaction;Dyslipidemia;Dysthymia;Emotional depression;Essential hypertension;Fatal stroke;Heart attack;Heart disease;High blood pressure;HTN;Hygroton;Hyperglycemia;Hyperpiesis;Hypertension;Hypertensive patients;Hyperuricemia;Hypoglycemics;Hypokalemia;Hyponatremia;Hypopotassemia;IDDM;Idiopathic hypertension;Idiosyncratic drug reactions;Injurious effects;Insulin;Insulin dependent diabetes;Insulin resistance;Isolated systolic hypertension;K deficiency;Kininase II inhibitors;Major depression;Mason-type diabetes;Maturity-onset diabetes mellitus;MI - myocardial infarction;MODY;Myocardial infarction;NIDDM;NIDDY;NNT;Non-insulin dependent diabetes mellitus;Nondiabetic patients;Oral hypoglycemic agents;Organic heart disease;Postoperative MI;Potassium depletion;Primary hypertension;Q-wave myocardial infarction;Raupasil;Reserpine;Serpasil;Sexual dysfunction;Side effects;Sodium depletion;Spurious hypokalemia;Structural heart disease;Systemic primary arterial hypertension;Systolic hypertension;Tenormin;Thiazide;Treatment of high blood pressure;Type II diabetes;Uncontrolled hypertension;Undesirable effects">
<META NAME="groups" CONTENT="BE97:0270;ACPJC;Therapeutics">
<META HTTP-EQUIV="Content-Type" Content="text-html; charset=Windows-1252">
<title>1999 - High-dose lisinopril was more effective than low-dose for reducing combined mortality and cardiovascular events in CHF</title>
</HEAD>
<BODY BGCOLOR=#FFFFFF TEXT=#000000>
<P CLASS="BEsection">Therapeutics</p>
<P CLASS="AbsTitl"><a name="diureticsreducedcardiovasculardiseaseeventsindiabeticandnondiabeticpatients"></a><a href="be4f86er.htm"></a>High-dose 
  lisinopril was more effective than low-dose for reducing combined mortality 
  and cardiovascular events in CHF</p>
<P CLASS="ACPSource">ACP Journal Club. 2000 July-Aug;133:4.<BR>
</p>
<P CLASS="Citation">Packer M, Poole-Wilson PA, Armstrong PW, et al., on behalf 
  of the ATLAS Study Group. <b>Comparative effects of low and high doses of the 
  angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality 
  in chronic heart failure.</b> Circulation. 1999 Dec 7;100:2312-8. </p>
<HR SIZE=2 COLOR=#3399CC>
<P CLASS="AbsHd">Question</p>
<P CLASS="AbsTxt">In patients with congestive heart failure (CHF), is high-dose 
  lisinopril more effective than low-dose lisinopril for reducing mortality and 
  hospitalization rates? </p>
<P CLASS="AbsHd">Design</p>
<P CLASS="AbsTxt">Randomized (allocation concealment unclear*), blinded (patients, 
  investigators, and outcome assessors),* controlled trial with 3-year follow-up. 
</p>
<P CLASS="AbsHd">Setting</p>
<P CLASS="AbsTxt">287 hospitals in 19 countries.</p>
<P CLASS="AbsHd">Patients</p>
<P CLASS="AbsTxt">3793 patients were screened, and 3164 (mean age 63.6 y, 80% 
  men) were studied. Inclusion criteria were New York Heart Association class 
  II, III, or IV CHF, despite use of diuretics for 2 months, and left ventricular 
  ejection fraction 30%. Exclusion criteria were recent revascularization procedure 
  or ischemic event, history of ventricular tachycardia, intolerance to angiotensin-converting 
  enzyme (ACE) inhibitors, serum creatinine levels &gt; 2.5 mg/dL, or noncardiac 
  disorders that could limit survival. Follow-up was 100%. </p>
<P CLASS="AbsHd">Intervention</p>
<P CLASS="AbsTxt">Patients received their usual CHF medications and were allocated 
  to lisinopril, 2.5 or 5.0 mg/d (n = 1596), or 30 mg/d (n = 1568). </p>
<P CLASS="AbsHd">Main outcome measures</p>
<P CLASS="AbsTxt">All-cause mortality. Secondary end points were cardiovascular 
  (CV) mortality and 5 combined end points.</p>
<P CLASS="AbsHd">Main results</p>
<P CLASS="AbsTxt">The groups did not differ for all-cause mortality (42.5% for 
  high-dose vs 44.9% for low-dose lisinopril, P = 0.13) or CV mortality (37.2% 
  vs 40.2%, P = 0.07). Patients in the high-dose group had lower rates of all-cause 
  mortality combined with all-cause hospitalization (P = 0.002), CV hospitalization 
  (P = 0.04), or CHF hospitalization (P &lt; 0.001) and lower rates of CV mortality 
  plus CV hospitalization (P = 0.03) (Table) than did patients in the low-dose 
  lisinopril group. </p>
<P CLASS="AbsHd">Conclusion</p>
<P CLASS="AbsTxt">High-dose lisinopril was more effective than low-dose lisinopril 
  for reducing the combined end points of all-cause mortality combined with either 
  all hospitalization, CV hospitalization, or CHF hospitalization and CV mortality 
  plus CV hospitalization for patients with CHF. </p>
<HR SIZE=2 COLOR=#3399CC>
<P CLASS="Grant">Source of funding: Zeneca Pharmaceuticals.</p>
<P CLASS="Grant">For correspondence: Dr. M. Packer, Division of Circulatory Physiology, 
  Columbia University College of Physicians and Surgeons, 630 West 168th Street, 
  New York, NY 10032, USA. FAX 212-305-7439. </p>
<P CLASS="Reprint">*See <a href="file:///E|/VA/Tabs/Assets/Glossary2.html">Glossary</a>.</p>
<HR SIZE=2 COLOR=#3399CC>
<P CLASS="CmHd"><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">High-dose 
  vs low-dose lisinopril for congestive heart failure (CHF)â€ </font></p>
<table border=0 cellpadding=3 cellspacing=0 width="100%">
  <tbody> 
  <tr valign=top> 
    <th class=colhdl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Outcomes 
      at 3 y </font></th>
    <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">High-dose 
      </font></th>
    <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Low-dose 
      </font></th>
    <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Hazard 
      ratio (95% CI) </font></th>
    <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">NNT 
      (CI) </font></th>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Mortality 
      plus hospitalization </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">79.7% 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">83.8% 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">0.88 
      (0.82 to 0.96) </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">26 
      (16 to 82) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Mortality 
      plus CV hospitalization </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">71.1% 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">74.1% 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">0.92 
      (0.84 to 0.99) </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">34 
      (17 to 284) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Mortality 
      plus CHF hospitalization </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">55.1% 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">60.4% 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">0.85 
      (0.78 to 0.93) </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">17 
      (12 to 37) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">CV 
      mortality plus CV hospitalization </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">69.4% 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">72.7% 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">0.91 
      (0.84 to 0.99) </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">30 
      (16 to 281) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  </tbody>
</table>
<p>
<P CLASS="Reprint">†CV = cardiovascular. Other abbreviations defined in <a href="../Assets/Glossary2.html">Glossary</a>; 
  NNT and its CI calculated by using hazard ratios provided in article. </p>
<hr size=2 color=#3399CC>
<P CLASS="AbsHd">Commentary</p>
<P CLASS="CmTxt">Large randomized controlled trials (RCTs) have shown that high-dose 
  ACE inhibitors are generally safe in CHF. Many clinicians remain concerned, 
  however, about safety issues and resort to the use of low-dose ACE inhibitors. 
  The Assessment of Treatment with Lisinopril and Survival (ATLAS) trial is the 
  largest RCT comparing a high- and low-dose ACE inhibitor in CHF. The results 
  show a trend toward decreased mortality and a modest reduction in combined end 
  points that include hospitalization and mortality. This finding is somewhat 
  surprising because a larger benefit with high-dose ACE inhibitors was anticipated. 
  The only other RCT that evaluated a low- and high-dose ACE-inhibitor strategy 
  in CHF was too small and too short to provide clear answers (1). Although the 
  benefits in the ATLAS study seem relatively modest, morbidity that includes 
  hospitalization is a major consideration in CHF, both from the patient's and 
  the clinician's perspective. </p>
<P CLASS="CmTxt">How are clinicians to interpret the results of the ATLAS trial? 
  First, the use of ACE inhibitors is well established as first-line therapy in 
  CHF, and every patient with clinical manifestations or with asymptomatic left 
  ventricular systolic dysfunction should be considered for ACE-inhibitor therapy. 
  Therapy should be initiated with caution, however, especially in elderly patients 
  and in those with renal dysfunction or low blood pressure. Patients should be 
  followed with careful and gradual increases in dose. If the drug is tolerated, 
  an attempt should be made to maximize the ACE inhibitor dose. If side effects 
  develop, however, maintaining patients on a low or intermediate dose is far 
  better than withdrawing therapy. In addition, as suggested by the ATLAS study 
  and many previous investigations, such symptoms as cough, hypotension, dizziness, 
  and renal dysfunction are not always related to ACE inhibitor use and may be 
  caused by CHF, concomitant illnesses, or other medications. Permanent withdrawal 
  of ACE inhibitors should be a last resort and considered only in patients who 
  clearly cannot tolerate this lifesaving intervention. </p>
<P CLASS="CmTxt">In addition, as suggested by the ATLAS study and many previous 
  investigations, such symptoms as cough, hypotension, dizziness, and renal dysfunction 
  are not always related to ACE inhibitor use and may be caused by CHF, concomitant 
  illnesses, or other medications. Permanent withdrawal of ACE inhibitors should 
  be a last resort and considered only in patients who clearly cannot tolerate 
  this lifesaving intervention. </p>
<P CLASS="CmTxt"><b>Eva Lonn, MD</b><BR>
  Hamilton General Hospital McMaster Clinic<BR>
  Hamilton, Ontario, Canada</p>
<HR SIZE=2 COLOR=#3399CC>
<P CLASS="CmRefHd">Reference</p>
<META NAME="Ref1">
<P CLASS="CmRef"><b>1.</b> <i>The NETWORK Investigators.</i> <b>Clinical outcome 
  with enalapril in symptomatic chronic heart failure: a dose comparison.</b> 
  Eur Heart J. 1998;19:481-9. </p>
<p></p>
</BODY>
</HTML>
